Bisphosphonate associated atypical femur fractures
Keywords:
Sudden death, ectopic pregnancy, broken ectopic pregnancy, hemoperitoneum, legal medicine.Abstract
Bisphosphonates are medications that are widely known for their antagonizing effect on bone resorption and their consequent reduction in the risk of fractures in patients with osteoporosis. Current literature provides evidence in terms of experimental and clinical data associating prolonged use of these drugs with an increase in the risk of atypical femur fractures. To establish if this association is clinically relevant, there lies a need for further studies that take into account other factors that might influence the occurrence of these type of fractures, like the osteoporotic disease itself, age, intake of other drugs and associated systemic illnesses.
References
2. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013;28(8):1729-37.
3. Neder Y, Fazio A, Valle P, et al. Fracturas atípicas de fémur proximal asociadas al uso prolongado de bifosfonatos. Revista de la Asociación Argentina de Ortopedia y Traumatología. 2018;83(3):152.
4. González-Macías J, del Pino-Montes J, Olmos J, Nogués X. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (3.ª versión actualizada 2014). Revista Clínica Española. 2015;215(9):515-526.
5. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29 (1): 1-23.
6. Laura E, Román F, Villarín A, et al. Fractura atípica de fémur secundaria al uso de bifosfonatos. Rev Clín Med Fam 2017; 10(2): 141-144.
7. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243-54.
8. Im G, Jeong S. Pathogenesis, Management and Prevention of Atypical Femoral Fractures. Journal of Bone Metabolism. 2015;22(1):1.
9. Dell R, Adams A, Greene D, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. Journal of Bone and Mineral Research. 2012;27(12):2544-2550.
10. Schilcher J, Koeppen V, Aspenberg P, et al. Risk of Atypical Femoral Fracture during and after Bisphosphonate Use. New England Journal of Medicine. 2014;371(10):974-976.
11. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. The Journal of clinical endocrinology and metabolism. 2010; 95(12): 5258–5265.
12. Nancollas G.H., Tang R., Phipps R.J., Gulde H.S., Wu W., Mangood A., et al: Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006; 38: 617-627.
13. Abrahamsen B., Eiken P., and Eastell R.: Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register based national cohort study. J Bone Miner Res 2009; 24:1095-1102.
14. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al: Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362:1761-1771.
Downloads
Published
Issue
Section
License
The intellectual property of accepted works belongs to their authors, however access to them is totally open and free, so they can be reproduced totally or partially with the only limitation of recognizing the authorship and the source of publication (Revista Medicina Legal de Costa Rica), as long as said exploitation does not have commercial character.
